Share |

Verisante Provides Operational Update

December 20, 2012 at 2:00 pm


VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, provides a year-end wrap up and operational update.

A summary of significant corporate highlights and recognition for 2012 include:

“2012 has been a year of foundation building and growth for Verisante,” said Thomas Braun, President & CEO. “We have successfully achieved our goals for this year and laid the groundwork for a full product launch of Verisante Aura™ in 2013 as we complete transfer to manufacturing processes this year. Our distribution partners are highly motivated and excited and we continue to work closely with them on sales and marketing support.”

The Company is finalizing the design of marketing and sales brochures, in addition to packaging solutions for Aura’s™ clean tips. Aura™ is a revolutionary device which has been developed with safety and ease of use as core principals embedded into a functional and attractive industrial design. The disposables will ensure the integrity of the system and safety for the patient.  Combined with our user friendly touch screen and graphical user interface, both doctors and patients can look forward to taking advantage of this ground breaking technology as we move into production this year for delivery and full product launch in 2013. Visit Verisante’s Facebook page at for an early sneak peek of some of the packaging.

The Company now has 22 full-time and part-time employees and consultants working directly on Verisante’s products, including Aura™, Core™ and other pipeline projects; in addition to dozens of contract manufacturers who have been qualified as parts and fulfillment suppliers and service providers.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was  named as the year’s top ranking Technology and Life Sciences Company on the TSX Venture 50.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:
Thomas Braun, President & CEO                   
Verisante Technology, Inc.                   
Telephone: (604) 605-0507                   

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top